| Assay ID | Title | Year | Journal | Article |
|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID655846 | Cytotoxicity against HEK293T cells at 20 uM by alamar blue assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655853 | Inhibition of PMA/ionomycin-induced NFkappaB activation at 0.25 to 25 uM in HEK293T cells by luciferase reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655879 | Inhibition of CFLT3 at 10 uM relative to control | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1736407 | Antagonist activity at human NOD2 expressed in HEK293 cells assessed as reduction in MDP-induced NF-kappaB activation preincubated for 1 hr followed by MDP stimulation and measured after 18 hrs by SEAP reporter gene based spectrophotometric analysis | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID655843 | Inhibition of NOD-1 mediated NFkappaB activation in HEK293T cells assessed as inhibition of gamma-tri-DAP-induced luciferase activity after 14 hrs by reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655858 | Solubility of the compound at pH 7.4 | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655872 | Plasma concentration in mouse at 15 mg/kg, ip at 120 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1736412 | Antagonist activity at NOD1 in human THP-1 cells assessed as reduction in C12-iE-DAP-induced IL-8 secretion at 20 uM preincubated for 1 hr followed by C12-iE-DAP stimulation and measured after 20 hrs by ELISA | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID655860 | Effective Permeability of the compound at 50 uM at pH 6.2 after 30 mins by PAMPA assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655861 | Effective Permeability of the compound at 50 uM at pH 7.4 after 30 mins by PAMPA assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1630469 | Inhibition of human NOD1 over-expressed in HEK-Blue cells assessed as inhibition of C12-iE-DAP induced NF-kappaB transcriptional activity measured as residual activity at 25 uM preincubated for 1 hr followed by addition of C12-iE-DAP measured after 18 hrs | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
| Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. |
| AID655874 | Inhibition of H1 histamine receptor at 10 uM | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655862 | Plasma protein binding in human at 1 uM after 4 hrs | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1178167 | Inhibition of NOD2 (unknown origin) expressed in HEK293T cells coexpressing NF-kappaB driven luciferase reporter gene by HTS primary assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway. |
| AID655863 | Plasma protein binding in human at 10 uM after 4 hrs | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1630472 | Selectivity ratio, ratio of IC50 for human NOD2 over-expressed in HEK-Blue cells to IC50 for human NOD1 over-expressed in HEK-Blue cells | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
| Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. |
| AID655875 | Inhibition of 5HT6 receptor at 10 uM | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655878 | Inhibition of AURKC at 10 uM relative to control | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655844 | Inhibition of NOD-2 mediated NFkappaB activation in HEK293T cells assessed as inhibition of MDP-induced luciferase activity after 14 hrs by reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655857 | Solubility of the compound at pH 6.2 | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655854 | Inhibition of doxorubicin-induced NFkappaB activation at 0.25 to 25 uM in HEK293T cells by luciferase reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1736406 | Antagonist activity at human NOD1 expressed in HEK293 cells assessed as reduction in C12-iE-DAP-induced NF-kappaB activation preincubated for 1 hr followed by C12-iE-DAP stimulation and measured after 18 hrs by SEAP reporter gene based spectrophotometric | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID1630471 | Inhibition of human NOD1 over-expressed in HEK-Blue cells assessed as inhibition of C12-iE-DAP induced NF-kappaB transcriptional activity preincubated for 1 hr followed by addition of C12-iE-DAP measured after 18 hrs by SEAP reporter gene assay | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
| Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. |
| AID1736409 | Selectivity index, ratio of IC50 for antagonist activity at human NOD2 cells expressed in HEK293 cells assessed as reduction in MDP induced NF-kappaB activation preincubated for 1 hr followed by MDPA stimulation and measured after 18 hrs by SEAP reporter | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID655848 | Selectivity ratio of IC50 for TNFalpha-induced NFkappaB activation to IC50 for NOD1-mediated NFkappaB activation in HEK293T cells | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655871 | Plasma concentration in mouse at 30 mg/kg, ip at 20 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655859 | Effective Permeability of the compound at 50 uM at pH 5 after 30 mins by PAMPA assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1630470 | Inhibition of human NOD2 over-expressed in HEK-Blue cells assessed as inhibition of C12-iE-DAP induced NF-kappaB transcriptional activity preincubated for 1 hr followed by addition of C12-iE-DAP measured after 18 hrs by SEAP reporter gene assay | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
| Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. |
| AID655867 | Metabolic stability in mouse plasma assessed as compound remaining at 1 uM after 180 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655881 | Inhibition of AURKA at 10 uM relative to control | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655868 | Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM preincubated for 10 mins measured after 60 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655873 | Plasma concentration in mouse at 30 mg/kg, ip at 120 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655882 | Cytotoxicity against human NCI60 cells | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655847 | Selectivity ratio of IC50 for NOD2-mediated NFkappaB activation to IC50 for NOD1-mediated NFkappaB activation in HEK293T cells | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1630468 | Cytotoxicity against HEK-Blue cells assessed as residual metabolic activity up to 25 uM measured after 24 hrs by MTS assay relative to untreated control | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
| Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. |
| AID1736402 | Cytotoxicity against human HEK293 cells expressing human NOD1 assessed as reduction in metabolic activity at 20 uM incubated for 18 hrs by MTS assay | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID655866 | Metabolic stability in human plasma assessed as compound remaining at 1 uM after 180 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655865 | Plasma protein binding in mouse at 10 uM after 4 hrs | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655852 | Inhibition of NOD-1 mediated NFkappaB activation in HEK293T cells assessed as inhibition of gamma-tri-DAP-induced luciferase activity at 0.25 to 25 uM by reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1736403 | Cytotoxicity against human HEK293 cells expressing human NOD2 assessed as reduction in metabolic activity at 20 uM incubated for 18 hrs by MTS assay | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID655880 | Inhibition of RIOK2 at 10 uM relative to control | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655876 | Inhibition of 5HT2B receptor at 10 uM | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655850 | Inhibition of NOD-2 in human MCF7 cells assessed as inhibition of MDP-induced IL8 secretion at 0.25 to 5 uM by ELISA | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655877 | Inhibition of AURKB at 10 uM relative to control | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655869 | Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM preincubated for 10 mins measured after 60 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1178166 | Inhibition of NOD1 (unknown origin) expressed in HEK293T cells coexpressing NF-kappaB driven luciferase reporter gene by HTS primary assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway. |
| AID1736414 | Antagonist activity at NOD1/TLR4 in human THP-1 cells assessed as reduction in C12-iE-DAP/LPS-induced TNF-alpha secretion at 20 uM preincubated for 1 hr followed by C12-iE-DAP/LPS stimulation and measured after 20 hrs by ELISA | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID1178168 | Selectivity ratio of IC50 for NOD2 (unknown origin) to IC50 for NOD1 (unknown origin) | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway. |
| AID655855 | Cytotoxicity against human Fa2N-4 cells after 24 hrs by ATP-lite assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655864 | Plasma protein binding in mouse at 1 uM after 4 hrs | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655849 | Inhibition of NOD-1 in human MCF7 cells assessed as inhibition of gamma-tri-DAP-induced IL8 secretion at 0.25 to 5 uM by ELISA | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655870 | Plasma concentration in mouse at 15 mg/kg, ip at 20 mins | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1736404 | Antagonist activity at human NOD1 expressed in HEK293 cells assessed as reduction in C12-iE-DAP-induced NF-kappaB activation at 10 uM preincubated for 1 hr followed by C12-iE-DAP stimulation and measured after 18 hrs by SEAP reporter gene based spectropho | 2020 | European journal of medicinal chemistry, Mar-15, Volume: 190 | Structural features and functional activities of benzimidazoles as NOD2 antagonists. |
| AID655851 | Inhibition of TNFalpha-induced IL8 secretion in human MCF7 cells at 0.25 to 5 uM by ELISA | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655856 | Solubility of the compound at pH 5 | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID655845 | Inhibition of TNFalpha-induced NFkappaB activation in HEK293T cells after 14 hrs by luciferase reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1345559 | Human nucleotide binding oligomerization domain containing 1 (NOD-like receptor family) | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| AID1345510 | Human nucleotide binding oligomerization domain containing 2 (NOD-like receptor family) | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
| Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |